JANX Q3 2025 Earnings — Janux Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

JANXJanux Therapeutics, Inc.

$852M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M+2177.9% YoY

Gross Profit

$9M95.0% margin

Operating Income

-$35M-352.5% margin

Net Income

-$24M-243.1% margin

EPS (Diluted)

$-0.39

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$1.0B

Total Liabilities

$48M

Stockholders' Equity

$977M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$439,000	+2177.9%
Gross Profit	$9M	$439,000	+2063.8%
Operating Income	-$35M	-$36M	+1.6%
Net Income	-$24M	-$28M	+13.4%